Pfizer reports positive data from prostate cancer combination therapy trial
In the trial, a TALZENNA plus XTANDI combination regimen offered overall survival (OS) improvement in metastatic castration-resistant prostate cancer (mCRPC) patients.
11 October 2024
11 October 2024
In the trial, a TALZENNA plus XTANDI combination regimen offered overall survival (OS) improvement in metastatic castration-resistant prostate cancer (mCRPC) patients.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.